FDA DEVICE FACTS
Auryon Atherectomy Catheter 1.7mm; Auryon Atherectomy Catheter 1.7mm, Hydrophilic Coating
Eximo Medical, Ltd.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Auryon™ Atherectomy System and Auryon Atherectomy Catheters with aspiration are indicated for use as atherectomy devices for arterial stenoses, including in-stent restenosis (ISR), and to aspirate thrombus adjacent to stenoses in native and stented infra-inguinal arteries. The Auryon™ Atherectomy System and Auryon Atherectomy Catheters without aspiration are indicated for use in the treatment, including atherectomy, of infra-inguinal stenoses and occlusions. COMPARISON OF TECHNOLOGY CHARACTERISTICS WITH THE PREDICATE DEVICE The proposed Auryon Atherectomy System is substantially equivalent to the predicate Auryon Atherectomy K233668. Both laser atherectomy devices have identical laser wavelength (355 nm), laser fluence levels (50 and 60 mJ/mm2), pulse rate (40Hz), pulse duration (10-25ns), maximum output (33.5mJ) and materials. The difference between the proposed device and predicate device is the addition of a 1.7mm catheter (1.75mm/0.069inch diameter) with a 150cm long working length. The 1.7mm catheter is offered both with and without a hydrophilic coating. The technological characteristic of the proposed device is substantially equivalent with the respect of the system design and function to that of the specified predicate device. DEVICE MODIFICATIONS AND RISK ASSOCIATED WITH THE DESIGN MODIFICATION(S) Modifications made to the Auryon Atherectomy System were limited to introducing a 1.7mm Catheter. There is no change to the principles of operations, indications for use, intended purpose, technology characteristics, between the proposed system and the predicate. The impact of the change as described within this submission were evaluated a part of the Risk analysis activity in terms of new/existing risks and new/existing failure modes. The results of this Risk Analysis activity were compared to the current risk Analysis; the conclusion drawn from this assessment, determined that the additional catheter size did not impact or modify an existing risk nor necessitate a new or modified risk. COMPARISON OF PERFORMANCE DATA The new 1.7mm Auryon Atherectomy System Catheter was tested using the same methods and acceptance criteria as the predicate device. Specific tests are listed below:
• Catheter Shaft OD, ID, Working Length
• Guard Tube Length
• Catheter Trackability (Simulated Use)
• Shaft Pull Test
• Inner Blade Pull Test
• Proximal Section Pull Test
• Luer Pull vs Handle Pull Test
• Distal Tip Evaluation
• Optical Functionality Test
• Catheter Torque Strength
• Fatigue Test
• Catheter Optical Durability
• Evaluation of Hydrophilic Coating
STERILIZATION VALIDATION Both the proposed 1.7mm Auryon Atherectomy System Catheter and the predicate Auryon Atherectomy System Catheters will be sterilized via the same process. Sterilization Validation on the proposed 1.7mm Auryon Atherectomy System Catheter was conducted per the below:
• Bioburden Determination
• LAL Testing 510(k) Number: K241553 Date of Preparation: June 27, 2024
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。